NK-cell engagers see another discontinuation
BeOne terminates a MUC1-targeting project.
VEGF bispecifics enter the conjugate era
JSKN027 will become the first ADC with this mechanism to enter human trials.
Karyopharm investors fasten their seatbelts
A binary Xpovio catalyst is set for March.
Compass points the way towards its next readout
Progression-free and overall survival data from Companion-002 are due this quarter.
ASCO-GU 2026 – late-breakers in focus
Welireg, Padcev, and a surprise fillip for Flare.
Astra’s Claudin reckoning approaches
Pivotal data are due soon with the Claudin18.2-targeting ADC sonesitatug vedotin.
AstraZeneca goes early with Gracell
AZD0120’s first pivotal trial will test settings as early as the second line.
